Project Grant HT94252410874
Award Date
9/1/24
Completion Date
8/31/27
Dollars Obligated
$924K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
The federal Project Grant award of $923,805.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant will fund the "Systematic Functional Dissection of Cancer Cell States in Lung Tumors" research project at the Sloan-Kettering Institute for Cancer Research in New York, NY. The project aims to advance understanding of cancer cell biology and develop novel therapeutic approaches for lung cancer, with...
The Sloan-Kettering Institute for Cancer Research was awarded a $923,999 Project Grant from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) to conduct research on understanding the effects of tobacco smoking on African American patients with lung cancer. The award will support a multi-year research initiative from July 1, 2024 to June 30, 2027. As a non-profit organization focused on cancer research and patient care, Sloan-Kettering Institute for...
This federal Project Grant award of $2,808,108.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by the Sloan-Kettering Institute for Cancer Research to investigate the role of clonal hematopoiesis in therapeutic resistance and metastatic relapse in breast cancer. The award period extends from March 1, 2024 to February 29, 2028. Through this funding, the Sloan-Kettering Institute will explore the...
The Project Grant award of $352,000.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) will support the Sloan-Kettering Institute for Cancer Research in augmenting the in vivo efficacy of a novel lanosterol synthase inhibitor for the treatment of glioblastoma. The award, with a performance period from September 1, 2025 to August 31, 2027, will enable Sloan-Kettering to conduct advanced biomedical research focused on transforming healthcare for...
The Defense Health Agency awarded a $619,500 Project Grant to the Sloan-Kettering Institute for Cancer Research, a non-profit organization in New York, NY. The grant is funded through the Military Medical Research and Development (CFDA 12.420) program and will support research to investigate the immunogenicity and targeting of shared neoantigens in adenoid cystic cancer over a 3-year period from September 1, 2023 to August 31, 2026. The research aims to transform health care for Service...
The federal Project Grant award, totaling $3,705,142.00, was issued by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the Sloan-Kettering Institute for Cancer Research. The award supports a Phase 2 study of sacituzumab govitecan-hziyin in patients with previously treated mesotheliomas. The research project, with a performance period from September 30, 2024 to September 29, 2028, aims to explore innovative approaches for the prevention,...
This federal Project Grant award for $704,000.00, awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research by the Sloan-Kettering Institute for Cancer Research in New York, NY. The research aims to investigate the role of the NF-I/A transcription factor in regulating fatty acid metabolism in kidney cancer. This multi-year project will run from September 1, 2024 to August 31, 2028. As the prime grantee, the Sloan-Kettering...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $1,194,586 project grant to the Sloan-Kettering Institute for Cancer Research, a non-profit organization located in New York, NY. The grant, awarded on September 30, 2023, will support a 3-year research project titled "COEVOLUTION OF METABOLISM AND IMMUNE MICROENVIRONMENT AS A DRIVER OF THERAPEUTIC RESPONSE AND METASTASIS IN CCRCC". Through this grant, the Sloan-Kettering Institute...
The Sloan-Kettering Institute for Cancer Research was awarded a $707,346 Project Grant from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420). This 3-year grant, effective September 1, 2024, supports Sloan-Kettering's cancer research initiatives, including investigations into the tumor microenvironment, mechanisms of metastasis, epigenetic alterations in cancer, resistance to cancer therapies, aging-related biology, and hematologic malignancies....
Sloan-Kettering Institute For Cancer Research was awarded a $796,500 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) for the period of July 15, 2023 through July 14, 2026. The grant will support research to develop novel tools to improve responses to DNA-damaging therapeutics in metastatic breast cancer. As the prime recipient, Sloan-Kettering Institute For Cancer Research will leverage its expertise in cancer biology,...